The price of Ubrelvy in Canada is not publicly available as the drug is not yet approved or marketed there [1]. Ubrelvy (ubrogepant) is an oral CGRP receptor antagonist used for the acute treatment of migraine with or without aura in adults [2].
When might Ubrelvy be available in Canada?
Ubrelvy has not received approval from Health Canada for sale in Canada. Its availability would depend on a future regulatory submission and approval process [1].
What is Ubrelvy's price in the United States?
In the United States, Ubrelvy is available in 50 mg and 100 mg tablets. The retail price for a 10-count supply of 100 mg tablets can range from approximately $480 to $500, though insurance and patient assistance programs can significantly reduce out-of-pocket costs [3][4].
How does Ubrelvy compare to other migraine treatments?
Ubrelvy is an oral medication that targets calcitonin gene-related peptide (CGRP) receptors, which play a role in migraine pain. It is distinct from triptans, which are older migraine medications that constrict blood vessels. Other CGRP-targeting medications include both oral options and injectable CGRP monoclonal antibodies used for migraine prevention [5][6].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie [2].
What are the potential side effects of Ubrelvy?
Common side effects reported for Ubrelvy include nausea, tiredness, and dry mouth [2]. Patients should discuss any concerns with their healthcare provider.